Our First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.
hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Our First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.
Transfer RNA (tRNA) is the essential, often overlooked, molecule that provides the critical translation of genetic code into the proteins that are the building blocks of life. We are creating engineered tRNAs with the power to overcome disease-causing issues in the genetic code as proteins are made.
“If you are working on something exciting that you really care about, you don’t have to be pushed. The vision pulls you.”
Steven Gillis has been a managing director at ARCH Venture Partners since 2005. Dr. Gillis was a Founder and Director of Corixa Corporation and served as the company’s Chief Executive Officer.
Sacha Mann is a Senior Partner at Takeda Ventures. She has a decade of experience in venture investing and complimentary skills in company creation, management as biotech CEO, business development, and R&D.
David focuses on the Bio-IT space. Prior to joining 8VC, David completed his Ph.D. in Biomedical Informatics at Stanford University, where he concurrently received an M.S. in Statistics.
Leslie J Williams, a 25-year biopharmaceutical industry veteran, is an experienced biotech CEO and board of directors’ member with demonstrated expertise in building companies, raising funds, and negotiating strategic collaborations.
PhD
Chairman of the Science Advisory Board
Craig is the Blais University Chair in Molecular Medicine at the University of Massachusetts Medical School (UMMS).
MD, PhD
Dr. John F. DiPersio is Chief of the Division of Oncology, Deputy Director of the Siteman Cancer Center at Washington University School of Medicine in St. Louis, and the Virginia E. and Samuel J. Golman Professor of Medicine.
DVM
Biotechnology Consultant
Page Bouchard is an independent biotechnology consultant with a focus on preclinical R&D and regulatory drug development.
MD, PhD
Dr. Oladapo Yeku is an Assistant Professor of Medicine at Harvard Medical School and a Clinical Assistant in Medicine at the Massachusetts General Hospital.
PhD
Dr. John Bell received his PhD from McMaster University in 1982. The three years that followed, he trained as a post-doctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England.
PhD
EVP, Head of Oncology Practice
Jeff leads the Oncology and Virology Practices at Cello Health BioConsulting, formerly Defined Health.
PhD
John Lueck is Assistant Professor in Department of Pharmacology and Physiology and is a member of The Center for RNA Biology the University of Rochester Medical Center
PhD
Christopher Ahern is a Professor in the Department of Molecular Physiology and Biophysics and the Iowa Neuroscience Institute.
If you are interested in partnering with us, reach out here at info@hcbioscience.com
Nature Biotechnology (2022)
Companies advance tRNA therapeutics to overcome mutant stoppages in protein synthesis shared by thousands of genetic diseases and cancers…and the field continues to expand with the arrival of hC Bioscience, a startup that emerged from stealth mode in late February with $24 million and a plan to fight cancer and rare diseases with tRNA…
hC Bioscience, Inc., a drug discovery and development company focused on first-in-class tRNA-based therapeutics targeting protein dysfunction, has closed a Series A financing of $24 million led by a strong syndicate of investors, including ARCH Venture Partners, Takeda Ventures and 8VC…
A new class of therapies based on transfer RNA could treat forms of cystic fibrosis, muscular dystrophy, genetic epilepsies, and more
Nonsense mutations change an amino acid codon to a premature termination codon (PTC) generally through a single-nucleotide substitution…
The appearance of the premature translation termination codons (PTCs)…
